Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo
- PMID: 9573023
Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo
Abstract
A variety of strategies have been attempted in the past to stably transduce natural killer (NK) cells with cytokine or other cellular genes. Here, we demonstrate the successful delivery of the interleukin-2 (IL-2) gene into two human NK cell lines, IL-2-dependent NK-92 and IL-2-independent YT, by retroviral transduction. An MuLV-based retroviral vector expressing human IL-2 and neor markers from a polycistronic message was constructed and transduced into a CRIP packaging cell line. By coincubation of NK cells with monolayers of CRIP cells or by using retrovirus-containing supernatants in a flow-through method, 10% to 20% of NK cells were stably transduced. Upon selection in the presence of increasing G418 concentrations, transduced NK cells were able to proliferate independently of IL-2 for more than 5 months and to secrete up to 5.5 ng/10(6) cells/24 h of IL-2. IL-2 gene-transduced NK-92 cells had an in vitro cytotoxicity against tumor targets that was significantly higher than that of parental cells and secreted interferon gamma (IFNgamma) and tumor necrosis factor alpha (TNFalpha) in addition to IL-2. Moreover, the in vivo antitumor activity of IL-2 gene-transduced NK-92 cells against established 3-day liver metastases in mice was greater than that of parental nontransduced NK cells. Stable expression of the IL-2 transgene in NK cells improved their therapeutic potential in tumor-bearing hosts. Thus, transduced NK cells secreted sufficient quantities of bioactive IL-2 to proliferate in vitro and mediated the antitumor effects both in vitro and in vivo in the absence of exogenous IL-2. These results suggest that genetic modification of NK cells ex vivo could be useful for clinical cancer therapy in the future.
Similar articles
-
In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.Cancer Gene Ther. 1997 Nov-Dec;4(6):366-76. Cancer Gene Ther. 1997. PMID: 9408607
-
Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.Exp Hematol. 1997 Oct;25(11):1140-8. Exp Hematol. 1997. PMID: 9328450
-
Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo.Int J Cancer. 1997 Jul 3;72(1):174-83. doi: 10.1002/(sici)1097-0215(19970703)72:1<174::aid-ijc25>3.0.co;2-i. Int J Cancer. 1997. PMID: 9212240
-
hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.Immunobiology. 2014 Jul;219(7):547-53. doi: 10.1016/j.imbio.2014.03.007. Epub 2014 Mar 20. Immunobiology. 2014. PMID: 24721706
-
Breast cancer gene therapy: transgenic immunotherapy.Breast Cancer Res Treat. 1994;31(2-3):349-56. doi: 10.1007/BF00666167. Breast Cancer Res Treat. 1994. PMID: 7881111 Review.
Cited by
-
NK cell-based immunotherapy for malignant diseases.Cell Mol Immunol. 2013 May;10(3):230-52. doi: 10.1038/cmi.2013.10. Epub 2013 Apr 22. Cell Mol Immunol. 2013. PMID: 23604045 Free PMC article. Review.
-
The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy.Biologics. 2021 Jul 7;15:265-277. doi: 10.2147/BTT.S290305. eCollection 2021. Biologics. 2021. PMID: 34262255 Free PMC article. Review.
-
Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.Front Immunol. 2020 Dec 16;11:607131. doi: 10.3389/fimmu.2020.607131. eCollection 2020. Front Immunol. 2020. PMID: 33391277 Free PMC article. Review.
-
Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy.Stem Cells Transl Med. 2024 Mar 15;13(3):230-242. doi: 10.1093/stcltm/szad087. Stem Cells Transl Med. 2024. PMID: 38142460 Free PMC article. Review.
-
NK cells as powerful therapeutic tool in cancer immunotherapy.Cell Oncol (Dordr). 2024 Jun;47(3):733-757. doi: 10.1007/s13402-023-00909-3. Epub 2024 Jan 3. Cell Oncol (Dordr). 2024. PMID: 38170381 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous